Meinertz T, Kasper W, Schumacher M, Just H
Medical Clinic III, University of Freiburg, Federal Republic of Germany.
Am J Cardiol. 1988 Sep 1;62(7):347-51. doi: 10.1016/0002-9149(88)90956-3.
A multicenter randomized trial of anisoylated plasminogen streptokinase activator complex (APSAC) versus heparin in patients with acute myocardial infarction of less than 4 hours' duration was undertaken in 19 hospitals. Of the 313 patients, 151 received heparin and 162 APSAC (30 U as intravenous injection). Within 28 days of hospital stay, 19 deaths (12.6%) occurred in the heparin group and 9 deaths (5.6%) in the APSAC group (p = 0.032). After 24 hours, patients in the APSAC group had a significantly lower incidence of cardiogenic shock (3.2 vs 9.5%, p = 0.031), asystole (3.8 vs 10.8%, p = 0.015) and need for resuscitation (5.1 vs 11.5%, p = 0.039). There was no difference in global and infarct-related ejection fraction between the 2 groups. Thus, APSAC favorably influences prognosis and clinical course in hospital.
在19家医院开展了一项多中心随机试验，比较茴香酰化纤溶酶原链激酶激活剂复合物（APSAC）与肝素对病程小于4小时的急性心肌梗死患者的疗效。313例患者中，151例接受肝素治疗，162例接受APSAC治疗（静脉注射30单位）。住院28天内，肝素组有19例死亡（12.6%），APSAC组有9例死亡（5.6%）（p = 0.032）。24小时后，APSAC组心源性休克发生率显著较低（3.2%对9.5%，p = 0.031），心脏停搏发生率较低（3.8%对10.8%，p = 0.015），复苏需求较低（5.1%对11.5%，p = 0.039）。两组的整体及梗死相关射血分数无差异。因此，APSAC对住院患者的预后和临床病程有积极影响。
